Next-generation sequencing (NGS) provides an effective, unbiased way to identify new coronavirus strains and other pathogens without prior knowledge of organisms.1 Sequencing was used to identify the novel coronavirus causing COVID-19 (SARS-CoV-2) early in the outbreak.2 Continued concern over fast spreading, novel variants of the SARS-CoV-2 coronavirus highlights the need for increased sequencing to detect mutations quickly and prevent the spread of new strains. NGS provides important evidence for public health officials, vaccine and drug developers, and researchers, enabling labs to:
Watch how Illumina developed the COVIDSeq Test in record time with the dedication and collaboration of all our employees in the video presentation. Also, learn how the COVIDSeq Assay enables labs to identify and track the emergence and prevalence of novel strains of SARS-CoV-2.
As the coronavirus mutates, new variants can emerge to potentially impact the public. Surveillance and monitoring are critical because mutations can result in greater transmissibility or infectiousness. These coronavirus mutations can make vaccines less effective/protective or even evade test diagnosis.3
NGS is a valuable technology for genomic surveillance of infectious diseases such as COVID-19. Not only can it track the prevalence of coronavirus mutant strains, NGS can also identify novel coronavirus mutations, unlike PCR technology. Using NGS, scientists can detect low-frequency minority variants and multiple polymorphisms as well as novel variants.
Genome-wide strain typing with NGS can help epidemiologists identify and characterize mutations quickly to prevent further spread. Strain-level tracing can support identification of outbreak clusters and transmission routes.
In contrast, PCR is designed to detect specific regions of the pathogen genome; it will not identify new mutations across rapidly evolving pathogen genomes. Furthermore, PCR performance can suffer if mutations occur in the primer or probe binding regions.
Detect and characterize SARS-CoV-2 coronavirus by sequencing the whole viral genome. This method involves analyzing the entire genome with ultra-deep sequencing of PCR amplicons.
Detect and characterize coronaviruses, flu viruses, and other pathogenic respiratory tract organisms, as well as associated antimicrobial resistance alleles. These insights can help researchers monitor respiratory infections and optimize infection control strategies. This method captures genomic regions of interest via hybridization to target-specific probes.
Comprehensively sequence all organisms in a given sample and identify novel pathogens such as coronaviruses. This NGS method can help accelerate outbreak investigations and support development of new laboratory tests.
Surveillance of SARS-CoV-2 | Detection and Surveillance of Respiratory Pathogens | Detect Novel Virus | |
---|---|---|---|
Testing Needs | Amplicon | Hybrid Capture | Shotgun Metagenomics |
Speed & Turnaround Time | |||
Scalable & Cost-Effective | |||
Identify Novel Pathogens | |||
Track Transmission | |||
Detect Mutations | |||
Identify Co-Infections & Complex Disease | |||
Detect Antimicrobial Resistance |
Adequately meets laboratory testing needs
Partially meets laboratory testing needs
Two leading infectious disease researchers discuss how genomic sequencing technologies are tackling the COVID-19 pandemic.
The COVID-19 pandemic has underscored the need for tools to detect and monitor emerging pathogens like SARS-CoV-2. NGS led to the initial detection of the coronavirus, and is accelerating test and vaccine development.
Learn about the broad applicability of NGS for responding to the COVID-19 pandemic, from initial detection and characterization of the novel coronavirus to monitoring, surveillance, and diagnostic detection.
Rapid hybrid capture sequencing for broad detection of respiratory pathogens (including SARS-CoV-2, flu viruses, and fungi) and associated antimicrobial resistance alleles.
Respiratory Pathogen ID/AMR Workflow Application NoteA rapid hybrid capture sequencing workflow for highly sensitive detection and characterization of coronaviruses, flu viruses, and other respiratory viruses.
MiniSeq Rapid reagents reduce sequencing run times to < 5 hours, allowing fast detection of coronaviruses and other respiratory viruses.
Genomics center established in record time to combat COVID-19 pandemic.
Read ArticleA Utah Public Health Lab director discusses how they've expanded their NGS operations in an effort to zero in on SARS-CoV-2 outbreak clusters and establish an infrastructure for future pandemics.
In a groundbreaking initiative, public health labs use Illumina technology to sequence the viral genomes of all positive COVID-19 tests in Australia and track COVID-19 across the country, rather than state by state.
A collaborative environment leveraging BaseSpace Correlation Engine helps COVID-19 researchers validate hypotheses around important pathways, biomarkers, and potential drug candidate leads.
How Aegis Sciences moved with the mutations, expanded capacity, and became one of the largest COVID sequencing operations in the world.
A campus lab sequences dust from vacuum bags to understand the variants and viral load of SARS-CoV-2 and other viruses.
In keeping with recommendations from the United States CDC and World Health Organization, Illumina recommends this procedure for decontaminating NGS instruments suspected or known to have come in contact with the novel coronavirus SARS-CoV-2 (2019-nCoV).
Use of ammonia-based cleaners and sanitizing products (frequently utilized to clean labs during the COVID-19 pandemic) in proximity to sequencing run setup can result in decreased sequencing run performance metrics. View tips on how to avoid these issues.
Learn how genomic-based TB surveillance can support public health officials in detection and transmission of outbreaks.
Get insights into how various NGS methods can offer breakthrough detection capabilities for antimicrobial resistance.
Learn how wastewater surveillance with NGS is helpful for community-level monitoring of emerging infectious diseases, mutation tracking, and variant trend tracking.